<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22614" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Migraine Headache</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pescador Ruschel</surname>
            <given-names>Marco A.</given-names>
          </name>
          <aff>Medical Center Santa Rita</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Pescador Ruschel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22614.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Migraine is a genetically influenced complex&#x000a0;neurological disorder characterized&#x000a0;by episodes of moderate-to-severe headaches, typically unilateral and frequently accompanied by nausea and heightened sensitivity to light and sound. These episodes, known as migraine attacks, can last hours to days and&#x000a0;significantly impact daily activities and the quality of life of individuals. Triggers for migraines vary widely among individuals and include factors such as stress, hormonal changes, specific foods, and environmental influences. Migraine attacks are recurrent and complex neurological events. The most prevalent type of migraine, accounting for 75% of cases, is migraine without aura.</p>
        <p>Diagnosis involves patient history, physical examination, and meeting specific diagnostic criteria. Management strategies encompass acute treatments for immediate relief during attacks, preventive therapies to reduce frequency and severity, and personalized lifestyle adjustments.&#x000a0;This activity reviews the pathophysiology, diagnosis, and management of migraines by providing healthcare providers with comprehensive knowledge about the latest evidence-based strategies for acute treatment, preventive therapies, and patient-centered approaches to care. Additionally, this activity highlights the essential role of interprofessional healthcare teams in improving patient outcomes and reducing the burden of this chronic condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify migraine headache features through comprehensive patient history and physical examination.</p></list-item><list-item><p>Screen patients for migraine triggers, including stress, hormonal changes, dietary factors, and environmental influences.</p></list-item><list-item><p>Select personalized lifestyle adjustments for patients to manage migraine triggers and improve treatment outcomes.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams to optimize migraine care and patient outcomes and ensure comprehensive management and support for patients with chronic migraines.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22614&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22614">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22614.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Migraine is a genetically influenced complex&#x000a0;neurological disorder&#x000a0;characterized&#x000a0;by episodes of moderate-to-severe headaches, typically unilateral and frequently accompanied by nausea and heightened sensitivity to light and sound. The word "migraine" is derived from the Greek word <italic toggle="yes">hemikrania</italic>, which was later converted into Latin as <italic toggle="yes">hemigranea</italic>. The French translation of the term is <italic toggle="yes">migraine</italic>.<xref ref-type="bibr" rid="article-22614.r1">[1]</xref>&#x000a0;</p>
        <p>Migraine is a common cause of disability and loss of work. Migraine attacks are complex and recurrent neurological&#x000a0;events that can unfold for hours to days and&#x000a0;significantly&#x000a0;impact&#x000a0;daily activities and the quality of life of individuals. The most prevalent type of migraine, accounting for 75% of cases, is migraine without aura.</p>
        <p>
<bold>Subtypes of Migraine </bold>
</p>
        <p>Migraines can be classified into the following subtypes according to the Headache Classification Committee of the International Headache Society.<xref ref-type="bibr" rid="article-22614.r2">[2]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>A migraine without aura: This subtype involves recurrent headache attacks lasting 4 to 72 hours. The pain is typically unilateral, pulsating&#x000a0;in quality, moderate-to-severe in intensity, aggravated by physical activity, and associated with nausea, light (photophobia), and sound sensitivity (phonophobia).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migraine with aura: This subtype features&#x000a0;recurrent, fully reversible attacks lasting minutes, typically presenting with 1 or more unilateral symptoms such as visual, sensory, speech and language, motor, brainstem, or retinal disturbances, usually followed by headache and other migraine symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic migraine: This is defined as a headache that occurs on 15 or more days in a month for more than&#x000a0;3 months, with migraine features present on at least&#x000a0;8 or more days in a month.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Probable migraine: This is a symptomatic migraine attack that lacks&#x000a0;1 of the features required to fulfill the criteria for&#x000a0;1 of the above and does not meet the criteria for another type of headache.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Episodic syndromes that may be associated with migraine are mentioned below.
<list list-type="bullet"><list-item><p>Recurrent gastrointestinal disturbances involve recurrent attacks of abdominal pain, discomfort, nausea, and vomiting that may be associated with migraines.</p></list-item><list-item><p>Benign paroxysmal vertigo involves brief, recurrent attacks of vertigo.</p></list-item><list-item><p>Benign paroxysmal torticollis&#x000a0;is characterized by recurrent episodes of head tilt to&#x000a0;1 side.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Complications of Migraine</bold>
</p>
        <p>Migraines can lead to various complications, including the following:&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Status migrainosus:&#x000a0;This is a debilitating migraine attack that lasts more than 72 hours.</p>
          </list-item>
          <list-item>
            <p>Persistent aura without infarction:&#x000a0;This refers to an aura that persists for more than&#x000a0;1 week without evidence of infarction on neuroimaging.</p>
          </list-item>
          <list-item>
            <p>Migrainous infarction:&#x000a0;This refers to 1 or more aura symptoms associated with brain ischemia on neuroimaging during a typical migraine attack.</p>
          </list-item>
          <list-item>
            <p>Migraine aura-triggered seizure:&#x000a0;This occurs during&#x000a0;an attack of migraine with aura, where a seizure is triggered.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Understanding the etiology of migraine headaches is crucial for effective diagnosis and treatment. Migraines are believed to result from a combination of genetic, environmental, and neurological factors. Research indicates that these headaches are linked to abnormal brain activity that affects nerve signals, chemicals, and blood vessels within the brain.</p>
        <p>
<bold>Genetics and Inheritance</bold>
</p>
        <p>Migraine has a strong genetic component, with the risk of migraines in affected relatives being 3 times greater than in relatives of unaffected individuals, although no specific inheritance pattern has been identified.<xref ref-type="bibr" rid="article-22614.r3">[3]</xref><xref ref-type="bibr" rid="article-22614.r4">[4]</xref>&#x000a0;The&#x000a0;genetic basis of migraine is complex, involving multiple loci and genes whose specific roles in pathogenesis remain uncertain. This is likely influenced by more than one genetic source at various genomic locations acting in tandem with environmental factors to influence susceptibility and disease characteristics in affected individuals.<xref ref-type="bibr" rid="article-22614.r5">[5]</xref>&#x000a0;Identifying these genes in individuals with migraines holds potential for predicting targeted prophylactic treatments.</p>
        <p>
<bold>Familial Hemiplegic Migraine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemiplegic migraine can occur in families or sporadically (where an individual is the first in the family to experience a hemiplegic migraine).<xref ref-type="bibr" rid="article-22614.r6">[6]</xref>&#x000a0;Channelopathies are responsible for the primary 3 types:
<list list-type="bullet"><list-item><p>Type 1 is caused by mutations in the <italic toggle="yes">CACNA1A</italic> gene (voltage-gated calcium channel &#x003b1;1A-subunit) on chromosome 19p13.<xref ref-type="bibr" rid="article-22614.r7">[7]</xref>&#x000a0;</p></list-item><list-item><p>Type 2 is caused by mutations in the <italic toggle="yes">ATP1A2</italic> gene (ATPase, Na+/K+ transporting &#x003b1;2-subunit) on chromosome 1q23.<xref ref-type="bibr" rid="article-22614.r8">[8]</xref></p></list-item><list-item><p>Type 3 is caused by mutations in the <italic toggle="yes">SCN1A</italic> gene (voltage-gated sodium channel type 1&#x003b1;-subunit).</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mutations in the <italic toggle="yes">PRRT2</italic> gene (proline-rich transmembrane 2) are recognized as a possible cause.<xref ref-type="bibr" rid="article-22614.r9">[9]</xref>&#x000a0;The&#x000a0;<italic toggle="yes">PRRT2</italic> gene encodes a protein that interacts with the SNAP25 (synaptosomal nerve-associated protein 25), which may pose a role in voltage-gated calcium channel regulation.<xref ref-type="bibr" rid="article-22614.r10">[10]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mutations in the <italic toggle="yes">SLC4A4</italic> gene (solute carrier family 4 member 4) have also been associated with familial forms of migraine.<xref ref-type="bibr" rid="article-22614.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes</bold>
</p>
        <p>MELAS is a syndrome characterized by mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. This multisystemic disorder, caused by maternal inheritance, can present as recurrent migraine headaches.<xref ref-type="bibr" rid="article-22614.r12">[12]</xref></p>
        <p>
<bold>Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy</bold>
</p>
        <p>CADASIL is an angiopathy with autosomal dominant inheritance caused by mutations in the <italic toggle="yes">NOTCH3</italic> gene (notch receptor 3) on chromosome 19. CADASIL can present with migraine with aura (prodrome in 80%) in nearly 50% of carriers.<xref ref-type="bibr" rid="article-22614.r13">[13]</xref></p>
        <p>
<bold>Retinal Vasculopathy with Cerebral Leukodystrophy</bold>
</p>
        <p>RVCL is an angiopathy primarily caused by C-terminal frame-shift mutations in the <italic toggle="yes">TREX1</italic> (3-prime repair exonuclease 1) gene, accounting for nearly 60% of cases.<xref ref-type="bibr" rid="article-22614.r14">[14]</xref></p>
        <p>
<bold>Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy</bold>
</p>
        <p>HIHRATL&#x000a0;is a novel hereditary autosomal dominant condition&#x000a0;that affects retinal and cerebral vessels.</p>
        <p>
<bold>Hereditary endotheliopathy with retinopathy, nephropathy, and stroke</bold>
</p>
        <p>HERNS is a cerebroretinal vasculopathy linked to&#x000a0;a&#x000a0;locus on chromosome 3p21.</p>
        <p>
<bold>Migraine Triggers</bold>
</p>
        <p>Withdrawal or exposure to several factors contributes to the development of migraine headaches.<xref ref-type="bibr" rid="article-22614.r15">[15]</xref>&#x000a0;A retrospective study found that 76% of the patients reported triggers.<xref ref-type="bibr" rid="article-22614.r16">[16]</xref>&#x000a0;Some factors are probable contributors, while others are possible or unproven. These factors include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stress affecting 80% of cases (probable factor)</p>
          </list-item>
          <list-item>
            <p>Hormonal changes in 65% of cases during menstruation, ovulation, and pregnancy (probable factor)</p>
          </list-item>
          <list-item>
            <p>Skipped meals, 57% of patients (probable factor)</p>
          </list-item>
          <list-item>
            <p>Weather changes affecting 53% of individuals (probable factor)</p>
          </list-item>
          <list-item>
            <p>Excessive or insufficient sleep affecting 50% of patients (possible factor)</p>
          </list-item>
          <list-item>
            <p>Odors, such as perfumes, colognes, and petroleum distillates, affecting 40% of cases</p>
          </list-item>
          <list-item>
            <p>Neck pain in 38% of cases</p>
          </list-item>
          <list-item>
            <p>Exposure to lights in 38% of cases (probable factor)</p>
          </list-item>
          <list-item>
            <p>Alcohol ingestion in 38% of individuals (wine as a probable factor)</p>
          </list-item>
          <list-item>
            <p>Smoking in 36% of patients (unproven factor)</p>
          </list-item>
          <list-item>
            <p>Late sleeping in 32% of cases</p>
          </list-item>
          <list-item>
            <p>Heat affecting 30% of cases</p>
          </list-item>
          <list-item>
            <p>Food in 27% of cases (aspartame as a possible factor and tyramine and chocolate as unproven factors)</p>
          </list-item>
          <list-item>
            <p>Exercise in 22% of cases</p>
          </list-item>
          <list-item>
            <p>Sexual activity in 5% of cases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Migraine is highly prevalent, affecting approximately 12% of the population, with annual rates reaching up to 17% among women and 6% among men.<xref ref-type="bibr" rid="article-22614.r17">[17]</xref><xref ref-type="bibr" rid="article-22614.r18">[18]</xref><xref ref-type="bibr" rid="article-22614.r19">[19]</xref>&#x000a0;Among&#x000a0;children, it is more prevalent in girls than boys.<xref ref-type="bibr" rid="article-22614.r20">[20]</xref>&#x000a0;The prevalence of migraine increases during puberty, peaks between ages 35 and 39, and tends to decrease later in life, particularly after menopause.<xref ref-type="bibr" rid="article-22614.r18">[18]</xref></p>
        <p>The adjusted prevalence of migraine is highest in North America, followed by South America, Central America, Europe, Asia, and Africa. Globally, it ranks as the second leading cause of disability.<xref ref-type="bibr" rid="article-22614.r21">[21]</xref>&#x000a0;</p>
        <p>Migraine&#x000a0;tends to run in families,<xref ref-type="bibr" rid="article-22614.r17">[17]</xref>&#x000a0;with a reported risk of 40% if&#x000a0;1 parent has a history of migraine, which increases to 75% when both parents have a migraine history and are affected.&#x000a0;This condition ranks consistently as the fourth or fifth most common reason for emergency room visits, accounting for approximately 3% of all annual emergency room visits.<xref ref-type="bibr" rid="article-22614.r22">[22]</xref>&#x000a0;Moreover, migraine is considered the second major cause of disability after back pain in terms of years lived with disability.<xref ref-type="bibr" rid="article-22614.r20">[20]</xref></p>
      </sec>
      <sec id="article-22614.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although not fully understood, the pathogenesis of migraine headaches involves multiple components of both the peripheral and central (CNS) nervous systems. This section describes some of the most well-understood concepts. According to the older vascular theory of migraine, headaches were thought to be produced by vasodilation and auras by vasoconstriction; however, this theory is no longer considered viable.<xref ref-type="bibr" rid="article-22614.r23">[23]</xref> Current theories suggest that multiple primary neuronal impairments lead to a series of intracranial and extracranial changes that cause migraines.<xref ref-type="bibr" rid="article-22614.r24">[24]</xref></p>
        <p>The activation of trigeminal afferents occurs through neuronal pannexin-1 mega channel opening and subsequent activation of caspase-1. This is followed by the release of proinflammatory mediators, activation of nuclear factor kappa-B (NF-kB), and the spreading of this inflammatory signal to trigeminal nerve fibers around the vessels of the pia mater.<xref ref-type="bibr" rid="article-22614.r25">[25]</xref>&#x000a0;This process triggers a series of cortical, meningeal, and brainstem events, provoking inflammation in the pain-sensitive meninges and resulting in headaches through central and peripheral mechanisms.<xref ref-type="bibr" rid="article-22614.r26">[26]</xref><xref ref-type="bibr" rid="article-22614.r27">[27]</xref>&#x000a0;This pathway can explain the cortical depression (which establishes the aura) and the latter prolonged activation of trigeminal nociception (which leads to headache).</p>
        <p>The cortical spreading depression of Le&#x000e3;o&#x02014;a propagating wave of neuronal and glial depolarization that initiates a cascade&#x02014;is hypothesized to cause the aura, activate trigeminal afferents, and alter the hematoencephalic barrier permeability by activating brain matrix metalloproteinases.<xref ref-type="bibr" rid="article-22614.r28">[28]</xref>&#x000a0;In migraine without aura, it is suggested that cortical spreading depression may occur in areas where depolarization is not consciously perceived, such as the cerebellum.<xref ref-type="bibr" rid="article-22614.r29">[29]</xref></p>
        <p>The anterior structures are primarily innervated by the ophthalmic division of the trigeminal nerve, which may account for pain in the anterior region of the head.&#x000a0;A convergence of fibers from the upper cervical roots exists, originating from neurons of the trigeminal nerve and ganglion at the trigeminal nucleus caudalis. This convergence may explain the distribution of pain from anterior to posterior, as these fibers ascend to the thalamus and sensory cortex.<xref ref-type="bibr" rid="article-22614.r30">[30]</xref>&#x000a0;</p>
        <p>Based on vasodilation, edema, and plasma protein extravasation, neurogenic inflammation results from the activation of nociceptors, particularly within the trigeminal system. This process is associated with the release of substance P, calcitonin gene&#x02013;related peptide (CGRP), and neurokinin A&#x02014;vasoactive neuropeptides liberated by stimulation of the trigeminal ganglion.<xref ref-type="bibr" rid="article-22614.r31">[31]</xref>&#x000a0;Elevated levels of these neuropeptides have been observed in the spinal fluid of patients with chronic migraines.<xref ref-type="bibr" rid="article-22614.r32">[32]</xref><xref ref-type="bibr" rid="article-22614.r33">[33]</xref> Neurogenic inflammation can lead to sensitization&#x02014;a process where neurons become more responsive to stimulation. This may explain clinical symptoms of pain and the transition from episodic migraine to chronic migraines.<xref ref-type="bibr" rid="article-22614.r34">[34]</xref></p>
        <p>Neuropeptides believed to play a role in migraine pathogenesis include the following:</p>
        <p><bold>Serotonin:&#x000a0;</bold>Serotonin is released from the brainstem serotonergic nuclei and is thought to be involved in migraine; however, the exact mechanisms are still debated. Between migraine attacks, serotonin levels are likely to decrease, potentially resulting in a deficiency in the serotonin pain inhibition system. This decrease could contribute to trigeminal system activation, thereby exacerbating migraine symptoms. Serotonin may exert its effects by directly influencing cranial vessels, central pain control pathways, or cortical projections from brainstem serotonergic nuclei.<xref ref-type="bibr" rid="article-22614.r35">[35]</xref><xref ref-type="bibr" rid="article-22614.r36">[36]</xref>&#x000a0;</p>
        <p><bold>Calcitonin gene-related peptide:</bold>&#x000a0;CGRP is abundant in trigeminal ganglion neurons and released from the peripheral and central nerve terminals. CGRP is secreted within the trigeminal ganglion. Upon release from peripheral terminals, CGRP stimulates increased synthesis of nitric oxide and subsequent sensitization of trigeminal nerves.<xref ref-type="bibr" rid="article-22614.r37">[37]</xref><xref ref-type="bibr" rid="article-22614.r38">[38]</xref>&#x000a0;CGRP acts as a potent vasodilator of cerebral and dural vessels, contributing to neurogenic inflammation, and it mediates pain transmission from trigeminal vessels to the CNS.</p>
        <p><bold>Pituitary adenylate cyclase-activating polypeptide:&#x000a0;</bold>PACAP may also have a significant role in mediating migraine attacks, as its concentration is elevated during the attacks, and infusion of PACAP may trigger migraines in susceptible patients.</p>
      </sec>
      <sec id="article-22614.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Migraine headaches typically progress through distinct phases that characterize the course of an attack, each with unique symptoms. Understanding these stages is crucial for effective management and patient education.</p>
        <p>The 4&#x000a0;phases identified in migraine attacks are as follows: <xref ref-type="bibr" rid="article-22614.r39">[39]</xref></p>
        <p><bold>Prodrome</bold>: Premonitory symptoms associated with hypothalamic activation (dopamine).<xref ref-type="bibr" rid="article-22614.r40">[40]</xref><xref ref-type="bibr" rid="article-22614.r41">[41]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Approximately 77% of patients experience prodromal symptoms for up to 24 to 48 hours before headache onset. This phase is more common in females than males (81% versus 64%).</p>
          </list-item>
          <list-item>
            <p>Common symptoms include yawning (34%), mood changes, lethargy, neck stiffness, sensitivity to light and sound, restlessness, difficulty focusing vision, feeling cold, cravings, sweating, increased energy, thirst, and edema.</p>
          </list-item>
        </list>
        <p><bold>Aura:</bold>&#x000a0;Changes in cortical function, blood circulation, and neurovascular integration occur in approximately 25% of cases.<xref ref-type="bibr" rid="article-22614.r2">[2]</xref><xref ref-type="bibr" rid="article-22614.r13">[13]</xref><xref ref-type="bibr" rid="article-22614.r42">[42]</xref><xref ref-type="bibr" rid="article-22614.r43">[43]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Auras can precede the headache or present it simultaneously.</p>
          </list-item>
          <list-item>
            <p>Auras are typically gradual, lasting less than 60 minutes, predominantly visual, and encompass positive and negative symptoms.
<list list-type="bullet"><list-item><p>Positive symptoms result from active release by neurons in the&#x000a0;CNS (such as bright lines or shapes, tinnitus, noises, paresthesias, allodynia, or rhythmic movements).</p></list-item><list-item><p>Negative symptoms indicate a lack or loss of function (such as reduced or lost vision, hearing, sensation, or movement).</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Auras&#x000a0;must be fully reversible by definition.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tingling sensations, usually present on 1 side of the face or a limb, are considered paresthesias.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The most common positive visual symptom is scintillating scotoma (an area of absent vision with a shimmering or glittering zigzag border).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The most common negative visual symptom is visual field defects.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visual auras are the most frequent.</p>
          </list-item>
          <list-item>
            <p>Sensory auras are also common and can follow visual symptoms or occur independently.</p>
          </list-item>
          <list-item>
            <p>Language auras, which consist of transient dysphasia, are infrequent.</p>
          </list-item>
          <list-item>
            <p>Motor auras are rare and involve complete or partial hemiplegia of the limbs and face.</p>
          </list-item>
        </list>
        <p><bold>Headache:</bold>&#x000a0;Additional changes in blood circulation and function of the brainstem, thalamus, hypothalamus, and cortex can occur.</p>
        <list list-type="bullet">
          <list-item>
            <p>The headache is often unilateral, generally with a pulsatile or throbbing feature, and increases in intensity within the first hours.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The intensity can correlate with nausea, vomiting, photophobia, phonophobia, rhinorrhea, lachrymation, allodynia, and osmophobia.</p>
          </list-item>
          <list-item>
            <p>The headache can last from hours to days.</p>
          </list-item>
          <list-item>
            <p>Patients may seek relief in dark places,&#x000a0;and the pain usually resolves with sleep.</p>
          </list-item>
        </list>
        <p><bold>Postdrome</bold>: Persistent blood changes with symptoms after headache termination.</p>
        <list list-type="bullet">
          <list-item>
            <p>This phase consists of movement-vulnerable pain in the exact location of the previous headache.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Common symptoms include exhaustion, dizziness, difficulty concentrating, and euphoria.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of migraine is based on patient history, physical examination, and fulfillment of diagnostic criteria. Demographic features of the patient, including age, gender, race, and profession, should also be noted.&#x000a0;Additional necessary information that&#x000a0;must be gathered from the patient consists of answers to relatively simple questions, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>When did the headache start?</p>
          </list-item>
          <list-item>
            <p>Where does it hurt? (specific location and irradiation)</p>
          </list-item>
          <list-item>
            <p>What is the intensity of the pain?</p>
          </list-item>
          <list-item>
            <p>How is the pain? What are the qualitative characteristics of pain?</p>
          </list-item>
          <list-item>
            <p>How long does the pain last?</p>
          </list-item>
          <list-item>
            <p>At which moment of the day does the pain appear?</p>
          </list-item>
          <list-item>
            <p>How has it evolved since it started?</p>
          </list-item>
          <list-item>
            <p>What is the frequency of appearance?</p>
          </list-item>
          <list-item>
            <p>What are the triggering situations?</p>
          </list-item>
          <list-item>
            <p>Are there simultaneous symptoms?</p>
          </list-item>
          <list-item>
            <p>Is it related to sleep?</p>
          </list-item>
          <list-item>
            <p>How does it get better or worse?</p>
          </list-item>
          <list-item>
            <p>Which medications do you take to make it better? What is the frequency of this medication?</p>
          </list-item>
        </list>
        <p>Patients should also be&#x000a0;queried about somatosensory disturbances, such as spreading unilateral numbness or tingling in the face and arm, as well as about&#x000a0;disturbances in speech or thinking. Some aura symptoms&#x000a0;may indicate&#x000a0;uncommon types of migraine and include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Motor weakness</p>
          </list-item>
          <list-item>
            <p>Dysarthria</p>
          </list-item>
          <list-item>
            <p>Hypacusis</p>
          </list-item>
          <list-item>
            <p>Diplopia</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Vertigo</p>
          </list-item>
          <list-item>
            <p>Tinnitus</p>
          </list-item>
          <list-item>
            <p>Decreased level of consciousness</p>
          </list-item>
        </list>
        <p>
<bold>Diagnostic Criteria for Migraine as per the International Classification of Headache Disorders</bold>
</p>
        <p>The International Classification of Headache Disorders (ICHD-3) describes the below-mentioned diagnostic criteria for migraine.<xref ref-type="bibr" rid="article-22614.r2">[2]</xref></p>
        <p>
<bold>Criterion B1. Migraine without aura</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>B1a: Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>B1b: Headache has at least&#x000a0;2 of the following characteristics:
<list list-type="bullet"><list-item><p>Unilateral location&#x000a0;</p></list-item><list-item><p>Pulsating quality&#x000a0;</p></list-item><list-item><p>Moderate-to-severe pain intensity</p></list-item><list-item><p>Aggravation by or causing avoidance of routine physical activity (walking or climbing stairs)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>B1c: During a headache, at least 1 of the following:
<list list-type="bullet"><list-item><p>Nausea and/or vomiting</p></list-item><list-item><p>Photophobia and phonophobia</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Criterion&#x000a0;B2. Migraine with aura</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>B2a: 1 or more of the fully reversible aura symptoms mentioned below.
<list list-type="bullet"><list-item><p>Visual</p></list-item><list-item><p>Sensory</p></list-item><list-item><p>Speech and language</p></list-item><list-item><p>Motor</p></list-item><list-item><p>Brainstem&#x000a0;</p></list-item><list-item><p>Retinal&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>B2b: At least&#x000a0;2 of the characteristics mentioned below.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;
<list list-type="bullet"><list-item><p>At least&#x000a0;1 aura symptom spreads gradually over&#x000a0;5 or more minutes</p></list-item><list-item><p>2 or more aura symptoms occur in succession</p></list-item><list-item><p>Each aura symptom lasts 5 to 60 minutes&#x000a0;</p></list-item><list-item><p>At least&#x000a0;1 aura symptom is unilateral</p></list-item><list-item><p>At least&#x000a0;1 aura symptom is positive&#x000a0;</p></list-item><list-item><p>The aura is accompanied, or followed within 60 minutes, by the headache</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Criterion&#x000a0;C.</bold>&#x000a0;On&#x000a0;8 days or more per month for more than&#x000a0;3 months, fulfilling any of the below-mentioned criteria.</p>
        <list list-type="bullet">
          <list-item>
            <p>Criteria B1b and B1c: For migraine without aura&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Criteria B2a and B2b: For migraine with aura&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Believed by the patient to be migraine headaches at onset and relieved by a triptan or ergot derivative</p>
          </list-item>
        </list>
        <p><bold>Criterion&#x000a0;D.</bold> Not better accounted for by another ICHD-3 diagnosis.</p>
        <p>
<bold>The International Classification of Headache Disorders Criteria for Migraine Without Aura</bold>
</p>
        <p>The criteria of ICHD-3 for migraine without aura are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>At least&#x000a0;5 attacks fulfilling criteria B to D&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Headache attacks that last 4 to 72 hours, untreated or unsuccessfully treated&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Headache that has at least&#x000a0;2 of the following criteria:
<list list-type="bullet"><list-item><p>Unilateral location</p></list-item><list-item><p>Pulsating quality</p></list-item><list-item><p>Moderate-to-severe pain intensity</p></list-item><list-item><p>Aggravation by or causing avoidance of routine physical activity (such as walking or climbing stairs)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>During headaches, at least&#x000a0;1 of the following:
<list list-type="bullet"><list-item><p>Nausea, vomiting, or both</p></list-item><list-item><p>Photophobia and phonophobia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Not better accounted for by another ICHD-3 diagnosis</p>
          </list-item>
        </list>
        <p>
<bold>The International Classification of Headache Disorders Criteria for Migraine With Aura</bold>
</p>
        <p>The criteria of ICHD-3 for migraine with aura are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>At least&#x000a0;2 attacks fulfilling the criteria from B to D.</p>
          </list-item>
          <list-item>
            <p>At least 1 or more of these fully reversible aura symptoms, including visual, sensory, speech and language, motor, brainstem, and retinal.</p>
          </list-item>
          <list-item>
            <p>At least&#x000a0;3 of the following&#x000a0;6 characteristics:
<list list-type="bullet"><list-item><p>At least&#x000a0;1 aura symptom spreads gradually over 5 minutes or more.</p></list-item><list-item><p>Two or more symptoms occur in succession.</p></list-item><list-item><p>Each aura symptom lasts 5 to 60 minutes.</p></list-item><list-item><p>At least&#x000a0;1 aura symptom is unilateral.</p></list-item><list-item><p>At least&#x000a0;1 aura symptom is positive.</p></list-item><list-item><p>The aura is accompanied, or followed within 60 minutes, by the headache.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Not better accounted for by another ICHD-3 diagnosis.</p>
          </list-item>
          <list-item>
            <p>Hemiplegic migraine is diagnosed when the aura consists of motor weakness.</p>
          </list-item>
          <list-item>
            <p>Migraine with brainstem aura (previously known as basilar artery migraine or basilar migraine) is diagnosed if the aura symptoms emerge from the brainstem (bilateral hemianopic visual disturbance, diplopia, vertigo, ataxia, dysarthria, tinnitus, hyperacusis, bilateral paresthesia, or numbness).</p>
          </list-item>
          <list-item>
            <p>Retinal migraine is diagnosed when the aura involves a monocular visual field defect.</p>
          </list-item>
        </list>
        <p>
<bold>The International Classification of Headache Disorders Criteria for Chronic Migraine</bold>
</p>
        <p>The criteria of ICHD-3 for chronic migraine are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (tension-type-like or migraine-like) on 15 or more days per month for more than&#x000a0;3 months and fulfilling criteria B and C.</p>
          </list-item>
          <list-item>
            <p>A patient who has had at least&#x000a0;5 attacks fulfilling the criteria for migraine without aura (B1) or migraine with aura (B2).</p>
          </list-item>
        </list>
        <p>Neuroimaging, such as computed tomography (CT) scan, magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), or magnetic resonance venography (MRV), is indicated in the following cases:<xref ref-type="bibr" rid="article-22614.r44">[44]</xref><xref ref-type="bibr" rid="article-22614.r45">[45]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Acute severe headache, especially if it is the first or worst episode (to exclude subarachnoid hemorrhage).</p>
          </list-item>
          <list-item>
            <p>Abnormal neurological examination, especially if there are unexplained symptoms or signs (such as confusion, stiff neck, papilledema, or epilepsy).</p>
          </list-item>
          <list-item>
            <p>Atypical headache characteristics</p>
          </list-item>
          <list-item>
            <p>Changes in the patient's typical headache features or patterns</p>
          </list-item>
          <list-item>
            <p>New episodes in patients aged 50 or older or those who are immunosuppressed</p>
          </list-item>
          <list-item>
            <p>Systemic or meningeal signs or symptoms (such as fever, weight loss, or fatigue)</p>
          </list-item>
          <list-item>
            <p>New neurological symptoms or signs on examination</p>
          </list-item>
          <list-item>
            <p>Headache not responding to treatment</p>
          </list-item>
          <list-item>
            <p>Headache lasting longer than 72 hours</p>
          </list-item>
          <list-item>
            <p>Significant change in the frequency, pattern, or severity of headaches</p>
          </list-item>
          <list-item>
            <p>Severe headache pain (or "worst headache of life") or headache causing awakening from sleep</p>
          </list-item>
          <list-item>
            <p>New-onset headache in patients with HIV infection or cancer</p>
          </list-item>
          <list-item>
            <p>Associated symptoms or signs suggestive of meningitis or stroke</p>
          </list-item>
        </list>
        <p>The commonly used acronym "SNOOP" can be used to aid in the determination of neuroimaging indications as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>"S" for systemic signs or symptoms and secondary risk factors</p>
          </list-item>
          <list-item>
            <p>"N" for neurological signs or symptoms</p>
          </list-item>
          <list-item>
            <p>"O" for onset</p>
          </list-item>
          <list-item>
            <p>"O" for older</p>
          </list-item>
          <list-item>
            <p>"P" for position-dependent intensity changes, the prior pattern changes, papilledema, and precipitated by Valsalva maneuvers</p>
          </list-item>
        </list>
        <p>Cerebrospinal fluid analysis and electroencephalogram are not typically performed unless seizure activity of an infectious etiology&#x000a0;must be excluded.</p>
      </sec>
      <sec id="article-22614.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of migraine headaches involves a multifaceted approach aimed at alleviating symptoms, preventing attacks, and improving patients' overall quality of life. Effective management typically combines acute treatments for immediate relief during attacks, preventive strategies to reduce frequency and severity, and personalized lifestyle modifications addressing individual triggers and patient needs.&#x000a0;</p>
        <p>
<bold>Acute or Abortive Treatments</bold>
</p>
        <p>Acute treatment aims to stop the progression of a migraine headache, which must be treated quickly and with a large single medication dose. Oral medications may be ineffective in patients with migraine-induced gastric stasis. Therefore, parenteral medication&#x000a0;may be the rule for some patients, especially those with nausea or vomiting.<xref ref-type="bibr" rid="article-22614.r46">[46]</xref><xref ref-type="bibr" rid="article-22614.r47">[47]</xref><xref ref-type="bibr" rid="article-22614.r48">[48]</xref> Therapy consists of stratified options as mentioned below and also in the <bold>Treatment Planning</bold> section (see <bold>Table 1.</bold>&#x000a0;Acute Therapy Options for Migraine).</p>
        <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs):</bold>&#x000a0;Ibuprofen (400-600 mg), naproxen (275-825 mg), diclofenac (65 mg), aspirin (900-1000 mg), or acetaminophen (1000 mg).<xref ref-type="bibr" rid="article-22614.r49">[49]</xref>&#x000a0;This drug class is usually prescribed for patients with mild-to-moderate attacks without nausea or vomiting.&#x000a0;If&#x000a0;an NSAID is ineffective, switching to another class of drug is recommended.</p>
        <p><bold>Triptans:</bold> Triptans are first-line treatments, especially effective in patients with allodynia. Options include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sumatriptan: This is administered as a subcutaneous (SQ) injection of 6 mg, nasal spray of 20 to 40 mg over 24 hours, nasal powder of 10 to 30 mg over 24 hours, or oral dose of 50 to 100 mg once.</p>
          </list-item>
          <list-item>
            <p>Zolmitriptan: This is administered as nasal 2.5 to 5 mg in a single dose or oral 2.5 mg in a single dose, not exceeding 10 mg in 24 hours.</p>
          </list-item>
          <list-item>
            <p>Eletriptan, rizatriptan, or almotriptan.</p>
          </list-item>
        </list>
        <p>Triptans&#x000a0;may be used with or without naproxen for moderate-to-severe attacks. Unlike NSAIDs, patients who do not respond well to a&#x000a0;triptan may respond to another, necessitating individualized therapy.</p>
        <p>Here are important considerations for the use of triptans in migraine management:</p>
        <list list-type="bullet">
          <list-item>
            <p>Triptans should be limited to less than 10 days of use per month to avoid medication overuse.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Due to their activation of 5-HT(1B) and 5-HT(1D) receptors on coronary and cerebral vessels, triptans are contraindicated in patients with ischemic stroke, ischemic heart disease, poorly-controlled hypertension, angina, pregnancy, and hemiplegic or basilar migraine. In patients with cardiovascular risks, lasmiditan, a selective serotonin 1F receptor agonist that does not induce vasoconstriction, is the preferred medication.</p>
          </list-item>
          <list-item>
            <p>Patients concurrently taking selective serotonin reuptake inhibitors or serotonin-noradrenaline reuptake inhibitors should be monitored for serotonin syndrome risk.</p>
          </list-item>
          <list-item>
            <p>Combining NSAIDs with triptans is often more effective than using either drug class alone. Initial therapy may include sumatriptan succinate 85 mg and naproxen sodium 500 mg in a single tablet.<xref ref-type="bibr" rid="article-22614.r50">[50]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Antiemetics:</bold>&#x000a0;Anti-nausea medications such as metoclopramide, chlorpromazine, or prochlorperazine are commonly used adjunctively with NSAIDs or triptans to reduce nausea and vomiting, particularly in emergency settings. Diphenhydramine may also be added to prevent dystonic reactions, primarily associated with metoclopramide.</p>
        <p><bold>Calcitonin gene&#x02013;related peptide antagonists:</bold>&#x000a0;CGRP, such as rimegepant (75 mg as a single dose) or ubrogepant, may be considered for patients who do not respond to conventional treatments or those with coronary artery disease.<xref ref-type="bibr" rid="article-22614.r51">[51]</xref>&#x000a0;</p>
        <p><bold>Selective serotonin 1F receptor agonist:</bold>&#x000a0;The US Food and Drug Administration (FDA) approved oral lasmiditan tablets in October 2019 for acute migraine treatment in adults. Initial doses of lasmiditan include 50 or 100 mg, and this is particularly effective for patients who cannot use triptans due to cardiovascular risks. Although doses&#x000a0;can escalate to 100 or 200 mg as needed, but no more than&#x000a0;1 dose should be administered within&#x000a0;24 hours. The significant&#x000a0;adverse effect is dizziness. Therefore, patients should refrain from engaging in potentially hazardous activities or driving a motor vehicle for at least 8 hours after each dose of lasmiditan.<xref ref-type="bibr" rid="article-22614.r52">[52]</xref>&#x000a0;</p>
        <p><bold>Ergots:</bold>&#x000a0;Ergots such as ergotamine and dihydroergotamine (intravenous [IV], intramuscular [IM], SQ, and intranasal use) are recommended for acute attacks via parenteral administration. They serve as effective bridge therapy for medication overuse headaches and status migrainosus. However, the effectiveness of ergotamine is not well-established, and it carries significant adverse effects such as cerebrovascular, cardiovascular, and peripheral ischemic complications.</p>
        <p><bold>Dexamethasone:</bold> This can reduce the recurrence of early headaches but does not provide immediate relief.<xref ref-type="bibr" rid="article-22614.r53">[53]</xref><xref ref-type="bibr" rid="article-22614.r54">[54]</xref>&#x000a0;</p>
        <p><bold>Transcutaneous supraorbital nerve stimulation:</bold> This can reduce intensity.<xref ref-type="bibr" rid="article-22614.r55">[55]</xref>&#x000a0;</p>
        <p><bold>Transcranial magnetic stimulation:</bold>&#x000a0;This has proved effective as a second-line treatment with no severe adverse effects. This can also be considered an option to treat chronic migraines&#x000a0;but is contraindicated in patients with epilepsy.<xref ref-type="bibr" rid="article-22614.r56">[56]</xref><xref ref-type="bibr" rid="article-22614.r57">[57]</xref><xref ref-type="bibr" rid="article-22614.r58">[58]</xref>&#x000a0;</p>
        <p><bold>Nonpainful remote electric neurostimulation:</bold> This&#x000a0;may be considered a first-line treatment in some patients.<xref ref-type="bibr" rid="article-22614.r59">[59]</xref><xref ref-type="bibr" rid="article-22614.r60">[60]</xref>&#x000a0;</p>
        <p><bold>Peripheral nerve blocking:</bold> This (occipital plexus and sphenopalatine ganglion) may also be considered.<xref ref-type="bibr" rid="article-22614.r61">[61]</xref><xref ref-type="bibr" rid="article-22614.r62">[62]</xref></p>
        <p>
<bold>Prophylactic or Preventive Treatments</bold>
</p>
        <p>Preventive treatment aims to reduce&#x000a0;migraine frequency, improve responsiveness to the severity and duration of acute attacks, and reduce disability.<xref ref-type="bibr" rid="article-22614.r63">[63]</xref><xref ref-type="bibr" rid="article-22614.r64">[64]</xref>&#x000a0;Patients should document their migraine triggers to effectively reduce their impact in the future.</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications for preventive treatment include:&#x000a0;&#x000a0;
<list list-type="bullet"><list-item><p>Frequent or long-lasting headaches</p></list-item><list-item><p>Attacks causing significant disability and reduced quality of life</p></list-item><list-item><p>Contraindications or failure with&#x000a0;acute therapies</p></list-item><list-item><p>Significant adverse effects from abortive therapies</p></list-item><list-item><p>Risk of medication overuse headache</p></list-item><list-item><p>Menstrual migraine (with short-term premenstrual prophylaxis)</p></list-item><list-item><p>Hemiplegic migraine</p></list-item><list-item><p>Brainstem aura migraine</p></list-item><list-item><p>Persistent aura without infarction</p></list-item><list-item><p>Migrainous infarction</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Preventive treatment agents&#x000a0;include (see<bold> Table 2. </bold>Preventive Therapy Options for Migraine):
<list list-type="bullet"><list-item><p>&#x003b2;-Blockers: Metoprolol and propranolol, especially in hypertensive and nonsmoking patients.</p></list-item><list-item><p>Antidepressants: Amitriptyline and venlafaxine, especially beneficial for patients with depression, anxiety disorders, and insomnia.</p></list-item><list-item><p>Anticonvulsants: Valproate acid and topiramate, especially recommended for patients with epilepsy.</p></list-item><list-item><p>Calcium channel blockers: Verapamil and flunarizine, especially recommended for women of childbearing age and patients with Raynaud phenomenon.</p></list-item><list-item><p>CGRP antagonists: Erenumab, fremanezumab, and galcanezumab.</p></list-item><list-item><p>Botulin toxin (onabotulinumtoxinA): Recommended for adult patients experiencing headaches 15 or more days per month and lasting 4 or more hours a day.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Alternative Treatments</bold>
</p>
        <p>Incorporating lifestyle changes requires patient commitment, with social support playing a vital role in enhancing mental health and encouraging active patient participation. The following therapies can also be included to improve the quality of life in patients suffering from migraine headaches:</p>
        <list list-type="bullet">
          <list-item>
            <p>Regular exercise</p>
          </list-item>
          <list-item>
            <p>Yoga</p>
          </list-item>
          <list-item>
            <p>Relaxation training</p>
          </list-item>
          <list-item>
            <p>Cognitive-behavioral therapy</p>
          </list-item>
          <list-item>
            <p>Biofeedback</p>
          </list-item>
          <list-item>
            <p>Reduction of triggers</p>
          </list-item>
          <list-item>
            <p>Detoxification</p>
          </list-item>
          <list-item>
            <p>Butterbur</p>
          </list-item>
          <list-item>
            <p>Melatonin</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Accurately diagnosing migraine headaches involves distinguishing them from other types of headaches and neurological conditions. The differential diagnosis entails carefully considering various factors and symptoms that may overlap with other disorders. This meticulous process ensures patients receive the most suitable and effective treatment for their condition.</p>
        <p>Diagnostic considerations in a patient with a migraine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tension-type headache</p>
          </list-item>
          <list-item>
            <p>Cluster headache</p>
          </list-item>
          <list-item>
            <p>Cerebral aneurysms</p>
          </list-item>
          <list-item>
            <p>Chronic paroxysmal hemicrania</p>
          </list-item>
          <list-item>
            <p>Dissection syndromes</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Subarachnoid/intracranial hemorrhage</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Temporal/giant cell arteritis</p>
          </list-item>
        </list>
        <p>Tension-type headaches typically present as bilateral pain lasting from 30 minutes to 7 days. Patients often describe a sensation of pressure or tightness but typically remain active without associated symptoms.</p>
        <p>Cluster headaches typically manifest as unilateral pain that abruptly begins around the eye or temple. These headaches rapidly escalate in intensity over minutes to become excruciating and continuous, lasting between 15 minutes to 3 hours. Associated symptoms include lacrimation (tearing) and redness of the eye, nasal congestion (rhinorrhea), pallor, sweating, Horner syndrome (drooping eyelid and constricted pupil on the affected side), agitation, and focal neurological symptoms. Cluster headaches are often triggered by alcohol consumption.</p>
      </sec>
      <sec id="article-22614.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>&#x000a0;<bold>Table 1. </bold>Acute Therapy Options for Migraine&#x000a0;</p>
        <table-wrap id="article-22614.table0" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class/Drug</bold>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<bold>Dosage Range</bold>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Notes/Contraindications</bold>
</td>
              </tr>
              <tr style="height: 142px;">
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">NSAIDs</td>
                <td style="width: 236.0625px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Aspirin&#x000a0;<xref ref-type="bibr" rid="article-22614.r49">[49]</xref></p></list-item><list-item><p>Ibuprofen</p></list-item><list-item><p>Naproxen</p></list-item><list-item><p>Diclofenac</p></list-item><list-item><p>Diclofenac epolamine</p></list-item><list-item><p>Tolfemanic acid</p></list-item><list-item><p>Celecoxib&#x000a0;<xref ref-type="bibr" rid="article-22614.r65">[65]</xref></p></list-item><list-item><p>Dexletoprofen</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>900-1000 mg</p></list-item><list-item><p>400-600 mg</p></list-item><list-item><p>275-825 mg</p></list-item><list-item><p>50-100 mg</p></list-item><list-item><p>65 mg</p></list-item><list-item><p>200 mg</p></list-item><list-item><p>120&#x000a0;mg</p></list-item><list-item><p>50 mg</p></list-item></list>
</td>
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>All NSAIDs have similar efficacy&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Nonopioid analgesic</td>
                <td style="width: 236.0625px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acetaminophen&#x000a0;<xref ref-type="bibr" rid="article-22614.r66">[66]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>1000-3000 g</p></list-item></list>
</td>
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acute life-threatening hepatotoxicity at doses &#x0003e;4 g/d.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 586px;">
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Sumatriptan)*&#x000a0;<xref ref-type="bibr" rid="article-22614.r67">[67]</xref></p>
</td>
                <td style="width: 236.0625px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sumatriptan (oral)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item><list-item><p>Sumatriptan (intranasal solution)&#x000a0;<xref ref-type="bibr" rid="article-22614.r68">[68]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item><list-item><p>Sumatriptan (intranasal powder)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (spray)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (SQ)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50-100&#x000a0;mg as a single dose, with a maximum dosage of 200 mg/d.</p></list-item></list>
<list list-type="bullet"><list-item><p>20 mg as a single dose in 1 nostril; if symptoms persist, may repeat dose after &#x02265;2 hours. The maximum dosage is 40 mg/d.</p></list-item></list>
<list list-type="bullet"><list-item><p>22 mg as a single dose; may repeat dose after &#x02265;2 hours if symptoms persist or return. The maximum dosage&#x000a0;is 44 mg/d.</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose in 1 nostril; may repeat dose after &#x02265;1 hour if symptoms persist or return. The maximum dosage&#x000a0;is 30 mg/d.</p></list-item></list>
<list list-type="bullet"><list-item><p>6 mg as a single dose; may repeat dose (usually same as the first dose) after &#x02265;1 hour if symptoms persist or return, or a lesser dosage if 6 mg was not tolerated. The maximum dosage is 6 mg/dose and 12 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>All formulations of triptans are contraindicated in patients with severe hepatic impairment.</p></list-item></list>
<list list-type="bullet"><list-item><p>Contraindicated in patients with cardiovascular illness due to the risk of prolonged QT interval on&#x000a0;electrocardiogram (ECG) and subsequent ventricular arrhythmias, including torsades de pointes (TdP) and ventricular fibrillation.</p></list-item></list>
<list list-type="bullet"><list-item><p>This formulation may also cause&#x000a0;dizziness, lethargy, tremors, vertigo, akathisia, dystonia, and pathological laughter.</p></list-item></list>
<list list-type="bullet"><list-item><p>Other vasospasm-related events include peripheral ischemia, ischemic colitis, splenic infarction,&#x000a0;and Raynaud disease.</p></list-item></list>
<list list-type="bullet"><list-item><p>This formulation should be avoided in patients with&#x000a0;uncontrolled hypertension&#x000a0;and&#x000a0;pregnancy.</p></list-item></list>
<list list-type="bullet"><list-item><p>Ocular&#x000a0;adverse effects include transient and permanent blindness and significant partial vision loss.</p></list-item></list>
<list list-type="bullet"><list-item><p>The use of concomitant serotonergic drugs may cause&#x000a0;serotonin syndrome.</p></list-item></list>
<list list-type="bullet"><list-item><p>Unpleasant taste is less common with intranasal zolmitriptan compared to intranasal sumatriptan.</p></list-item></list>
<list list-type="bullet"><list-item><p>Patients who do not respond to a&#x000a0;triptan may respond to another.</p></list-item></list>
<list list-type="bullet"><list-item><p>Naratriptan and frovatriptan have a slower&#x000a0;onset and lower efficacy.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 108px;">
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Naratriptan)&#x000a0;<xref ref-type="bibr" rid="article-22614.r69">[69]</xref></p>
</td>
                <td style="width: 236.0625px; height: 108px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Naratriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 108px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;4 hours. The maximum dosage is 2.5 mg/dose and 5 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Using within 24 hours of an ergotamine preparation or a different triptan is not advised.</p></list-item></list>
<list list-type="bullet"><list-item><p>Contraindicated with severe renal impairment (CrCl &#x0003c;15 mL/min).</p></list-item></list>
</td>
              </tr>
              <tr style="height: 164px;">
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Zolmitriptan)</p>
</td>
                <td style="width: 236.0625px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Zolmitriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Zolmitriptan (intranasal)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;2.5 mg as a single dose; may repeat dose after &#x02265;2 hours. The maximum dosage is 5 mg/dose and 10 mg/d.<xref ref-type="bibr" rid="article-22614.r70">[70]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>2.5 to 5 mg as a single dose; may repeat dose after &#x02265;2 hours. The maximum dosage is 5 mg/dose and 10 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Refer to the section on sumatriptan for the&#x000a0;adverse effects of triptans.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 82px;">
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Frovatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Frovatriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose; may repeat dose after &#x02265;2 hours if needed. The maximum dosage is 2.5 mg/dose and 5 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Slower onset&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Almotriptan)&#x000a0;</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almotriptan&#x000a0;</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>12.5 mg as a single dose; may repeat dose after &#x02265;2 hours when needed. The maximum dosage is 12.5 mg/dose and 25 mg/d.<xref ref-type="bibr" rid="article-22614.r71">[71]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Reduce dose to half in patients with hepatic impairment&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Rizatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rizatriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>5-10 mg as a single dose; may repeat dose after &#x02265;2 hours if needed. The maximum dosage is 20-30 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Propranolol increases rizatriptan levels by 70%, necessitating a downward adjustment in the dose of rizatriptan in these patients.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Eletriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Eletriptan&#x000a0;<xref ref-type="bibr" rid="article-22614.r72">[72]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>40 mg as a single dose; may repeat dose after &#x02265;2 hours if needed. The maximum dosage is 40 mg/dose and 80 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Primarily metabolized by cytochrome P450 enzyme CYP3A4, this medication should not be administered within at least 72 hours of treatment with other drugs that are potent CYP3A4 inhibitors, such as itraconazole, ketoconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, and nelfinavir.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Antiemetics</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Metoclopramide (IV, IM, oral)&#x000a0;<xref ref-type="bibr" rid="article-22614.r73">[73]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Prochlorperazine (IV, IM)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-20 mg as a single dose.</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IV route is preferred for metoclopramide. Pretreatment with diphenhydramine is recommended to prevent akathisia and other acute dystonic reactions.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">CGRP antagonists</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rimegepant&#x000a0;<xref ref-type="bibr" rid="article-22614.r74">[74]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Ubrogepant&#x000a0;<xref ref-type="bibr" rid="article-22614.r75">[75]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>75 mg every other day, with a maximum dosage of 75 mg/d.</p></list-item></list>
<list list-type="bullet"><list-item><p>50-100 mg as a single dose; may repeat dose after &#x02265;2 hours if needed. The maximum dosage is 200 mg/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Administration at the onset of a migraine attack may improve treatment response.</p></list-item></list>
<list list-type="bullet"><list-item><p>This is used as&#x000a0;second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p></list-item></list>
<list list-type="bullet"><list-item><p>Further studies are required to establish efficacy and safety.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Serotonin 5-HT1F receptor agonist</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lasmiditan&#x000a0;<xref ref-type="bibr" rid="article-22614.r76">[76]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50-100 mg as a single dose; may increase to 100 or 200 mg as a single dose if needed. Repeat doses have not established efficacy.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Administration early in the course of a migraine attack may improve treatment response.</p></list-item></list>
<list list-type="bullet"><list-item><p>Used as second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p></list-item></list>
<list list-type="bullet"><list-item><p>A major adverse effect is dizziness (9%-17%). Wait for at least 8 hours between dosing and driving or operating heavy machinery.</p></list-item></list>
<list list-type="bullet"><list-item><p>This formulation may enhance the CNS depressant effects of alcohol.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Ergot derivative</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Dihydroergotamine&#x000a0;<xref ref-type="bibr" rid="article-22614.r77">[77]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IM:&#x000a0;1 mg as a single dose; may repeat hourly as required. The maximum dosage is 3 mg/d and 6 mg/week.</p></list-item></list>
<list list-type="bullet"><list-item><p>IV:&#x000a0;1 mg as a single dose; may repeat hourly as required. The maximum dosage is 2 mg/d and 6 mg/week.</p></list-item></list>
<list list-type="bullet"><list-item><p>SQ: 1 mg as a single dose; may repeat&#x000a0;every 2 hours as required. The maximum dosage is 3 mg/d and 6 mg/week.</p></list-item></list>
<list list-type="bullet"><list-item><p>Intranasal:&#x000a0;0.5 mg per spray: 1 spray (0.5 mg) into each nostril. Repeat after 15 min (total of 4 sprays per dose). The maximum dosage is 4 sprays (1 dose)/d.</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Use is contraindicated in severe hepatic or renal impairment, pregnancy, and breastfeeding.</p></list-item></list>
<list list-type="bullet"><list-item><p>Also contraindicated in patients with hypertension or ischemic heart disease.</p></list-item></list>
<list list-type="bullet"><list-item><p>Avoid use&#x000a0;within 24 hours of triptans or ergot-like agents.</p></list-item></list>
<list list-type="bullet"><list-item><p>Use&#x000a0;with potent inhibitors of CYP3A4 (including azole antifungals, protease inhibitors, and some macrolide antibiotics)&#x000a0;should be avoided.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>&#x000a0;*Adverse effects in this section pertain to all triptans unless specified.</p>
        <table-wrap id="article-22614.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Preventive Therapy Options for Migraine</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="2" cellpadding="5">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 158px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class</bold>
</td>
                <td style="width: 179px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 173px; height: 15px;" rowspan="1" colspan="1">
<bold>Dosage Range</bold>
</td>
                <td style="width: 217.53125px; height: 15px;" rowspan="1" colspan="1">
<bold>Adverse Effects/Contraindications</bold>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">&#x003b2;-Adrenoceptor blockers&#x000a0;<xref ref-type="bibr" rid="article-22614.r78">[78]</xref></td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Propranolol</p></list-item><list-item><p>Metoprolol</p></list-item><list-item><p>Timolol</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>80-240 mg</p></list-item><list-item><p>50-150 mg</p></list-item><list-item><p>10-20 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Contraindicated in patients with asthma, syncope, or heart blockage.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">Antidepressants</td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amitriptyline</p></list-item><list-item><p>Nortriptyline</p></list-item><list-item><p>Venlafaxine</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10-150 mg</p></list-item><list-item><p>25-100 mg</p></list-item><list-item><p>37.5-150 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Somnolence</p></list-item><list-item><p>Insomnia and hypertension</p></list-item></list>
</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 158px; height: 37px;" rowspan="1" colspan="1">Calcium-channel blockers</td>
                <td style="width: 179px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Verapamil&#x000a0;<xref ref-type="bibr" rid="article-22614.r79">[79]</xref></p></list-item></list>
</td>
                <td style="width: 173px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>180-480 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Constipation, hypotension, and edema</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">Antiepileptic drugs&#x000a0;<xref ref-type="bibr" rid="article-22614.r78">[78]</xref></td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Divalproex sodium</p></list-item><list-item><p>Topiramate</p></list-item><list-item><p>Gabapentin</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>200-1500 mg</p></list-item><list-item><p>25-150 mg</p></list-item><list-item><p>300-1800 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Weight gain, thrombocytopenia, and tremors</p></list-item><list-item><p>Renal calculi, amnesia, glaucoma, disequilibrium, and weight loss</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">CGRP monoclonal antibodies</td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Erenumab</p></list-item><list-item><p>Galcanezumab</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>70-140 mg every&#x000a0;4 weeks, SQ</p></list-item><list-item><p>120 mg monthly, SQ</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Injection site reactions, muscle spasms, and hypersensitivity reactions</p></list-item><list-item><p>Injection site reactions, vertigo, pruritus, and constipation</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">Botulinum toxin</td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>OnabotulinumtoxinA&#x000a0;<xref ref-type="bibr" rid="article-22614.r80">[80]</xref><xref ref-type="bibr" rid="article-22614.r81">[81]</xref><xref ref-type="bibr" rid="article-22614.r82">[82]</xref></p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>31 individual injections per session of 0.1 mL (5 Units) each, divided and administered across specific head and neck muscle areas, totaling 155 total Units</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Neck pain and headache</p></list-item><list-item><p>Irritation at the injection site</p></list-item><list-item><p>Drooping eyelids</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Reference for <bold>Table 2</bold>.<xref ref-type="bibr" rid="article-22614.r83">[83]</xref></p>
      </sec>
      <sec id="article-22614.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of migraine headaches varies widely among individuals, but with appropriate management, many patients can achieve significant relief and an improved quality of life. While migraines are a chronic condition with no definitive cure, advancements in treatment options, including preventive medications and lifestyle modifications, can substantially reduce the frequency and severity of attacks.</p>
        <p>Early diagnosis and intervention are critical, as they help tailor personalized treatment plans that can prevent the progression of chronic migraines. Chronic migraines can revert to episodic migraines in 26% to 70% of patients. Prolonged remissions are common; however, some patients experience a pattern of alternating between episodic and chronic states.</p>
        <p>The severity and frequency of&#x000a0;migraines can diminish with age.<xref ref-type="bibr" rid="article-22614.r84">[84]</xref>&#x000a0;Episodes increase during puberty and continue to climb until 35 to 39 years of age, decreasing later in life,&#x000a0;particularly after menopause.<xref ref-type="bibr" rid="article-22614.r18">[18]</xref>&#x000a0;Although some individuals may experience a decrease in migraine frequency with age, others may continue to have persistent symptoms. Overall, ongoing medical care and patient education are key to managing migraines effectively and enhancing long-term outcomes.</p>
      </sec>
      <sec id="article-22614.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Migraine headaches can lead to numerous complications that significantly affect patients' lives. Understanding these potential issues is essential for healthcare professionals to manage and mitigate long-term impacts on patients' health.</p>
        <p>Complications of migraine headaches include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Status migrainosus, which is a debilitating migraine attack lasting over 72 hours</p>
          </list-item>
          <list-item>
            <p>Migrainous infarction</p>
          </list-item>
          <list-item>
            <p>Migraine aura-triggered seizure</p>
          </list-item>
          <list-item>
            <p>Persistent aura without infarction</p>
          </list-item>
          <list-item>
            <p>Work disability and loss of productivity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with migraine headaches often require consultations with various healthcare professionals to manage their condition effectively. Neurologists conduct detailed evaluations and develop comprehensive treatment plans. Psychologists or psychiatrists may address accompanying mental health issues, such as anxiety or depression, which are common in migraine sufferers.</p>
        <p>In addition, nutritionists offer guidance on dietary triggers, and physical therapists provide strategies to alleviate migraine-associated muscle tension. In some cases, pain management specialists explore advanced treatment options. This multidisciplinary approach ensures holistic care, addressing all aspects of the patient's well-being.</p>
      </sec>
      <sec id="article-22614.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Timely diagnosis and management of migraine headaches are crucial, given their potential to be debilitating and impact quality of life significantly. Effective patient education is key to empowering individuals to manage their condition better. Patients should be informed about the different phases of migraine headaches and the benefits of abortive and preventive therapies. Patients should also be educated about lifestyle changes,&#x000a0;including regular exercise,&#x000a0;adequate hydration, and relaxation techniques, which are also important in reducing the frequency and severity of migraine attacks. Encouraging&#x000a0;patients to maintain a headache diary can help identify patterns and triggers effectively. Additionally, patients should be instructed to seek medical attention if symptoms worsen or new neurological symptoms occur, which may warrant neuroimaging.</p>
      </sec>
      <sec id="article-22614.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Understanding migraine headaches involves recognizing several critical facts that highlight their impact and management challenges. These salient points include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cortical spreading depression is the probable cause of the aura, which can activate trigeminal nerve afferents and alter hematoencephalic barrier permeability. Trigeminovascular system activation can initiate neurogenic inflammation related to migraine headaches.</p>
          </list-item>
          <list-item>
            <p>Migraine attacks are recurrent and unfold over hours to days through a cascade of events.</p>
          </list-item>
          <list-item>
            <p>Typical migraines progress through phases&#x02014;a prodrome, an aura, a headache, and a postdrome.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>There is no&#x000a0;one-size-fits-all approach to treating migraines. Each case requires individualized treatment tailored to its specific comorbidities.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22614.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Treating&#x000a0;migraine patients&#x000a0;requires the efforts and collaboration of an interprofessional healthcare team. The integrated care pathway provided by the healthcare team to patients must be combined with an evidence-based approach to planning and evaluating all joint activities. Primary care clinicians, including physicians and advanced practitioners, may seek the expertise of an internist, neurologist, or headache specialist if there is any doubt regarding the diagnosis.</p>
        <p>Nurses and psychologists contribute to team management by educating patients on lifestyle adjustments, providing mental health support, guiding medication detoxification for overuse, and offering recommendations on medication use. Pharmacists are critical in the team by verifying proper dosing and identifying potential drug interactions, particularly in chronic migraine treatments.&#x000a0;</p>
        <p>All interprofessional healthcare team members must document observed changes in patient status and promptly communicate with other team members. This ensures timely adjustments in diagnostic or therapeutic strategies as needed. Open communication among healthcare team members is essential for providing optimal care to patients and achieving the best possible outcomes. Collaboration, shared decision-making, and effective communication are necessary for achieving optimal&#x000a0;results.</p>
      </sec>
      <sec id="article-22614.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22614&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22614">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/migraine-headaches/migraine-headache-migraine/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22614">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22614/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22614">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22614.s18">
        <title>References</title>
        <ref id="article-22614.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>The history of migraine from Mesopotamian to Medieval times.</article-title>
            <source>Cephalalgia</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>15 Suppl 15</volume>
            <fpage>1</fpage>
            <page-range>1-3</page-range>
            <pub-id pub-id-type="pmid">8749238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merikangas</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Risch</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Merikangas</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Weissman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Migraine and depression: association and familial transmission.</article-title>
            <source>J Psychiatr Res</source>
            <year>1988</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-29</page-range>
            <pub-id pub-id-type="pmid">3404480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lozito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Staffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Alessandro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sacquegna</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Romeo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Segregation analysis of migraine in 128 families.</article-title>
            <source>Cephalalgia</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-5</page-range>
            <pub-id pub-id-type="pmid">3527442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Vries</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Anttila</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Freilinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wessman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaunisto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kallela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Artto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vijfhuizen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>G&#x000f6;bel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dichgans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kubisch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Palotie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terwindt</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>van den Maagdenberg</surname>
                <given-names>AM</given-names>
              </name>
              <collab>International Headache Genetics Consortium</collab>
            </person-group>
            <article-title>Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set.</article-title>
            <source>Cephalalgia</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>604</fpage>
            <page-range>604-14</page-range>
            <pub-id pub-id-type="pmid">25633374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ploton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbance</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Depienne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tournier-Lasserve</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Sep</month>
            <day>14</day>
            <volume>75</volume>
            <issue>11</issue>
            <fpage>967</fpage>
            <page-range>967-72</page-range>
            <pub-id pub-id-type="pmid">20837964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Dudding</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Baloh</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>No mutations in CACNA1A and ATP1A2 in probands with common types of migraine.</article-title>
            <source>Arch Neurol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>926</fpage>
            <page-range>926-8</page-range>
            <pub-id pub-id-type="pmid">15210532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prontera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sarchielli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Cupini</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Caproni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siliquini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy.</article-title>
            <source>Cephalalgia</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-72</page-range>
            <pub-id pub-id-type="pmid">23918834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimi-Fakhari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saffari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The evolving spectrum of PRRT2-associated paroxysmal diseases.</article-title>
            <source>Brain</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>138</volume>
            <issue>Pt 12</issue>
            <fpage>3476</fpage>
            <page-range>3476-95</page-range>
            <pub-id pub-id-type="pmid">26598493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarvis</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Zamponi</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels.</article-title>
            <source>Cell Calcium</source>
            <year>2005</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>483</fpage>
            <page-range>483-8</page-range>
            <pub-id pub-id-type="pmid">15820397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Paesschen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stalmans</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bergmans</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Legius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Riant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Jonghe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mikoshiba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimadzu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiohara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Al-Gazali</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2010</year>
            <month>Sep</month>
            <day>07</day>
            <volume>107</volume>
            <issue>36</issue>
            <fpage>15963</fpage>
            <page-range>15963-8</page-range>
            <pub-id pub-id-type="pmid">20798035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Eom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS).</article-title>
            <source>Pediatr Neurol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>64</volume>
            <fpage>59</fpage>
            <page-range>59-65</page-range>
            <pub-id pub-id-type="pmid">27671241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Saper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Migraine headache is present in the aura phase: a prospective study.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Nov</month>
            <day>13</day>
            <volume>79</volume>
            <issue>20</issue>
            <fpage>2044</fpage>
            <page-range>2044-9</page-range>
            <pub-id pub-id-type="pmid">23115208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stam</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gschwendter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hodgkinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kempster</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kotschet</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>van Duinen</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Maat-Schieman</surname>
                <given-names>MLC</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>PTVM</given-names>
              </name>
              <name>
                <surname>de Smet</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>de Wolff-Rouendaal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dijkman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pelzer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kolar</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fintak</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Grand</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Liapis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hajj-Ali</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kruit</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>van Buchem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dichgans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frants</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>van den Maagdenberg</surname>
                <given-names>AMJM</given-names>
              </name>
              <name>
                <surname>Haan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baloh</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Terwindt</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.</article-title>
            <source>Brain</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>139</volume>
            <issue>11</issue>
            <fpage>2909</fpage>
            <page-range>2909-2922</page-range>
            <pub-id pub-id-type="pmid">27604306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Behbehani</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Toward a rational understanding of migraine trigger factors.</article-title>
            <source>Med Clin North Am</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>911</fpage>
            <page-range>911-41</page-range>
            <pub-id pub-id-type="pmid">11480265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The triggers or precipitants of the acute migraine attack.</article-title>
            <source>Cephalalgia</source>
            <year>2007</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>394</fpage>
            <page-range>394-402</page-range>
            <pub-id pub-id-type="pmid">17403039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and burden of migraine in the United States: data from the American Migraine Study II.</article-title>
            <source>Headache</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>646</fpage>
            <page-range>646-57</page-range>
            <pub-id pub-id-type="pmid">11554952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <collab>AMPP Advisory Group</collab>
            </person-group>
            <article-title>Migraine prevalence, disease burden, and the need for preventive therapy.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Jan</month>
            <day>30</day>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-9</page-range>
            <pub-id pub-id-type="pmid">17261680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vetvik</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.</article-title>
            <source>Lancet Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-87</page-range>
            <pub-id pub-id-type="pmid">27836433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Migraine.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>04</day>
            <volume>166</volume>
            <issue>7</issue>
            <fpage>ITC49</fpage>
            <page-range>ITC49-ITC64</page-range>
            <pub-id pub-id-type="pmid">28384749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>GBD 2016 Headache Collaborators</collab>
            <article-title>Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>954</fpage>
            <page-range>954-976</page-range>
            <pub-id pub-id-type="pmid">30353868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies.</article-title>
            <source>Headache</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>496</fpage>
            <page-range>496-505</page-range>
            <pub-id pub-id-type="pmid">29527677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Asghar</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.</article-title>
            <source>Lancet Neurol</source>
            <year>2013</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>454</fpage>
            <page-range>454-61</page-range>
            <pub-id pub-id-type="pmid">23578775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Noseda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borsook</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Migraine: multiple processes, complex pathophysiology.</article-title>
            <source>J Neurosci</source>
            <year>2015</year>
            <month>Apr</month>
            <day>29</day>
            <volume>35</volume>
            <issue>17</issue>
            <fpage>6619</fpage>
            <page-range>6619-29</page-range>
            <pub-id pub-id-type="pmid">25926442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karatas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erdener</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gursoy-Ozdemir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eren-Ko&#x000e7;ak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Dalkara</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Spreading depression triggers headache by activating neuronal Panx1 channels.</article-title>
            <source>Science</source>
            <year>2013</year>
            <month>Mar</month>
            <day>01</day>
            <volume>339</volume>
            <issue>6123</issue>
            <fpage>1092</fpage>
            <page-range>1092-5</page-range>
            <pub-id pub-id-type="pmid">23449592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreou</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of migraine as a chronic evolutive condition.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Dec</month>
            <day>23</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <pub-id pub-id-type="pmid">31870279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Boas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.</article-title>
            <source>Nat Med</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-42</page-range>
            <pub-id pub-id-type="pmid">11821897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gursoy-Ozdemir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bolay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bermpohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cortical spreading depression activates and upregulates MMP-9.</article-title>
            <source>J Clin Invest</source>
            <year>2004</year>
            <month>May</month>
            <volume>113</volume>
            <issue>10</issue>
            <fpage>1447</fpage>
            <page-range>1447-55</page-range>
            <pub-id pub-id-type="pmid">15146242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nedergaard</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deciphering migraine.</article-title>
            <source>J Clin Invest</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>119</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-9</page-range>
            <pub-id pub-id-type="pmid">19104145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pritlove-Carson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Floyd</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical analysis of cells attached to teflon membranes following guided tissue regeneration.</article-title>
            <source>J Periodontol</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>969</fpage>
            <page-range>969-73</page-range>
            <pub-id pub-id-type="pmid">1282152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain.</article-title>
            <source>J Anesth</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-139</page-range>
            <pub-id pub-id-type="pmid">30448975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riesco</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cernuda-Moroll&#x000f3;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuropeptides as a Marker for Chronic Headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">28281109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anapindi</surname>
                <given-names>KDB</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Romanova</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Rubakhin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tipton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dripps</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sheets</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sweedler</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Pradhan</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models.</article-title>
            <source>Mol Cell Proteomics</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>2447</fpage>
            <page-range>2447-2458</page-range>
            <pub-id pub-id-type="pmid">31649062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chronic migraine: A process of dysmodulation and sensitization.</article-title>
            <source>Mol Pain</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>14</volume>
            <fpage>1744806918767697</fpage>
            <pub-id pub-id-type="pmid">29642749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Serotonergic mechanisms in the migraine brain - a systematic review.</article-title>
            <source>Cephalalgia</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-264</page-range>
            <pub-id pub-id-type="pmid">27013238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>N&#x000f8;rgaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eiberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lehel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>High brain serotonin levels in migraine between attacks: A 5-HT<sub>4</sub> receptor binding PET study.</article-title>
            <source>Neuroimage Clin</source>
            <year>2018</year>
            <volume>18</volume>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">29387527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyengar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Ossipov</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>CGRP and the Trigeminal System in Migraine.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-681</page-range>
            <pub-id pub-id-type="pmid">30982963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Role of CGRP in Migraine.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>255</volume>
            <fpage>121</fpage>
            <page-range>121-130</page-range>
            <pub-id pub-id-type="pmid">30725283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The evolution of a migraine attack - a review of recent evidence.</article-title>
            <source>Headache</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>413</fpage>
            <page-range>413-9</page-range>
            <pub-id pub-id-type="pmid">23278169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karsan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Imaging the Premonitory Phase of Migraine.</article-title>
            <source>Front Neurol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>140</fpage>
            <pub-id pub-id-type="pmid">32269547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laurell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Artto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bendtsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>H&#x000e4;ggstr&#x000f6;m</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000f6;derstr&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tronvik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wessman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zwart</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kallela</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Premonitory symptoms in migraine: A cross-sectional study in 2714 persons.</article-title>
            <source>Cephalalgia</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>951</fpage>
            <page-range>951-9</page-range>
            <pub-id pub-id-type="pmid">26643378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <pub-id pub-id-type="pmid">31492106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Dongen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Haan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Symptoms related to the visual system in migraine.</article-title>
            <source>F1000Res</source>
            <year>2019</year>
            <volume>8</volume>
            <pub-id pub-id-type="pmid">31448081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Testing for Migraine and Other Primary Headaches.</article-title>
            <source>Neurol Clin</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>707</fpage>
            <page-range>707-725</page-range>
            <pub-id pub-id-type="pmid">31563228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawasli</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Chicoine</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dacey</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Choosing Wisely: a neurosurgical perspective on neuroimaging for headaches.</article-title>
            <source>Neurosurgery</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5; quiz 6</page-range>
            <pub-id pub-id-type="pmid">25255253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Taiwan Headache Society</surname>
                <given-names>TGSOTHS</given-names>
              </name>
            </person-group>
            <article-title>Medical Treatment Guidelines for Acute Migraine Attacks.</article-title>
            <source>Acta Neurol Taiwan</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-96</page-range>
            <pub-id pub-id-type="pmid">29250761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cameron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kotb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skidmore</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>55 Suppl 4</volume>
            <fpage>221</fpage>
            <page-range>221-35</page-range>
            <pub-id pub-id-type="pmid">26178694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Acute Migraine Treatment in Adults.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-93</page-range>
            <pub-id pub-id-type="pmid">25877672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biglione</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gitin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hennekens</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers.</article-title>
            <source>Am J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-416</page-range>
            <pub-id pub-id-type="pmid">31712099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandes</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kudrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>O'Carroll</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Spruill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Lener</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Apr</month>
            <day>04</day>
            <volume>297</volume>
            <issue>13</issue>
            <fpage>1443</fpage>
            <page-range>1443-54</page-range>
            <pub-id pub-id-type="pmid">17405970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ubrogepant for the Treatment of Migraine.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Dec</month>
            <day>05</day>
            <volume>381</volume>
            <issue>23</issue>
            <fpage>2230</fpage>
            <page-range>2230-2241</page-range>
            <pub-id pub-id-type="pmid">31800988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Dozier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <collab>COL MIG-301 Study Group</collab>
            </person-group>
            <article-title>Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>91</volume>
            <issue>24</issue>
            <fpage>e2222</fpage>
            <page-range>e2222-e2232</page-range>
            <pub-id pub-id-type="pmid">30446595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giamberardino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Affaitati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costantini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute headache management in emergency department. A narrative review.</article-title>
            <source>Intern Emerg Med</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-117</page-range>
            <pub-id pub-id-type="pmid">31893348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirbaha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delavar-Kasmaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erfan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of the Concurrent Intravenous Injection of Dexamethasone and Metoclopramide for Pain Management in Patients with Primary Headaches Presenting to Emergency Department.</article-title>
            <source>Adv J Emerg Med</source>
            <year>2017</year>
            <season>Fall</season>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <pub-id pub-id-type="pmid">31172058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Shnayderman Yugrakh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winegarner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial.</article-title>
            <source>Cephalalgia</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">30449151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Aug</month>
            <day>22</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">28831756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kinsella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giffin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipscombe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Weatherall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program.</article-title>
            <source>J Headache Pain</source>
            <year>2015</year>
            <volume>16</volume>
            <fpage>535</fpage>
            <pub-id pub-id-type="pmid">26055242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starling</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shamim</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hindiyeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Chiacchierini</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>May</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>1038</fpage>
            <page-range>1038-1048</page-range>
            <pub-id pub-id-type="pmid">29504483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarnitsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Grosberg</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Burstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ironi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1240</fpage>
            <page-range>1240-1252</page-range>
            <pub-id pub-id-type="pmid">31074005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gruper</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ironi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Jul</month>
            <day>22</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <pub-id pub-id-type="pmid">31331265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korucu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dagar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000c7;orbacioglu</surname>
                <given-names>&#x0015e;K</given-names>
              </name>
              <name>
                <surname>Emektar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cevik</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-218</page-range>
            <pub-id pub-id-type="pmid">29744871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crespi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bratbak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jamt&#x000f8;y</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tronvik</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1229</fpage>
            <page-range>1229-1239</page-range>
            <pub-id pub-id-type="pmid">31342515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Feb</month>
            <day>26</day>
            <volume>80</volume>
            <issue>9</issue>
            <fpage>869</fpage>
            <page-range>869-70</page-range>
            <pub-id pub-id-type="pmid">23439705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Worthington</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gladstone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dilli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leroux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
              <collab>Canadian Headache Society Acute Migraine Treatment Guideline Development Group</collab>
            </person-group>
            <article-title>Canadian Headache Society Guideline: acute drug therapy for migraine headache.</article-title>
            <source>Can J Neurol Sci</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>5 Suppl 3</issue>
            <fpage>S1</fpage>
            <page-range>S1-S80</page-range>
            <pub-id pub-id-type="pmid">23968886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-70</page-range>
            <pub-id pub-id-type="pmid">31647577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Knaggs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Dec</month>
            <day>27</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD012227</fpage>
            <pub-id pub-id-type="pmid">28027389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>28</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD009108</fpage>
            <pub-id pub-id-type="pmid">24865446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Feb</month>
            <day>15</day>
            <volume>2012</volume>
            <issue>2</issue>
            <fpage>CD009663</fpage>
            <pub-id pub-id-type="pmid">22336867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havanka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-80</page-range>
            <pub-id pub-id-type="pmid">10972633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ramadan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kudrow</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Earl</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1210</fpage>
            <page-range>1210-8</page-range>
            <pub-id pub-id-type="pmid">9371896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Zanchin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geraud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Klippel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diaz-Insa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gobel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ivanoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Falques</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fortea</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.</article-title>
            <source>Cephalalgia</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-91</page-range>
            <pub-id pub-id-type="pmid">18294251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Oldman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>McQuay</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Eletriptan for acute migraine.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2001</year>
            <issue>3</issue>
            <fpage>CD003224</fpage>
            <pub-id pub-id-type="pmid">11687056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-306</page-range>
            <pub-id pub-id-type="pmid">22309235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Forshaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Coric</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>394</volume>
            <issue>10200</issue>
            <fpage>737</fpage>
            <page-range>737-745</page-range>
            <pub-id pub-id-type="pmid">31311674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Nov</month>
            <day>19</day>
            <volume>322</volume>
            <issue>19</issue>
            <fpage>1887</fpage>
            <page-range>1887-1898</page-range>
            <pub-id pub-id-type="pmid">31742631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dennehy</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.</article-title>
            <source>Brain</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>142</volume>
            <issue>7</issue>
            <fpage>1894</fpage>
            <page-range>1894-1904</page-range>
            <pub-id pub-id-type="pmid">31132795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Winner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jeleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hocevar-Trnka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrewsbury</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>&#x000ae;</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.</article-title>
            <source>Headache</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>1214</fpage>
            <page-range>1214-1226</page-range>
            <pub-id pub-id-type="pmid">34363701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of migraine headache.</article-title>
            <source>CMAJ</source>
            <year>2010</year>
            <month>Apr</month>
            <day>20</day>
            <volume>182</volume>
            <issue>7</issue>
            <fpage>E269</fpage>
            <page-range>E269-76</page-range>
            <pub-id pub-id-type="pmid">20159899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markley</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Verapamil and migraine prophylaxis: mechanisms and efficacy.</article-title>
            <source>Am J Med</source>
            <year>1991</year>
            <month>May</month>
            <day>17</day>
            <volume>90</volume>
            <issue>5A</issue>
            <fpage>48S</fpage>
            <page-range>48S-53S</page-range>
            <pub-id pub-id-type="pmid">2039020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corasaniti</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bagetta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicotera</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tarsitano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tonin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sandrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Scuteri</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.</article-title>
            <source>Toxins (Basel)</source>
            <year>2023</year>
            <month>May</month>
            <day>12</day>
            <volume>15</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37235366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanteri-Minet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ducros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Francois</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olewinska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nikodem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dupont-Benjamin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of onabotulinumtoxinA (BOTOX&#x000ae;) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.</article-title>
            <source>Cephalalgia</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>14</issue>
            <fpage>1543</fpage>
            <page-range>1543-1564</page-range>
            <pub-id pub-id-type="pmid">36081276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaterian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaterian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghanaatpisheh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbasi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Daniali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jahromi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sanie</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Abdoli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.</article-title>
            <source>Pain Res Manag</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>3284446</fpage>
            <pub-id pub-id-type="pmid">35401888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Medications for migraine prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">16417067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22614.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serrano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WBF</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Oct</month>
            <day>04</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <pub-id pub-id-type="pmid">28980171</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
